Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claim 1-7 (canceled).

Claim 8 (currently amended): ~~The oligodeoxynucleotide of claim 1,~~ A substantially pure or isolated oligodeoxynucleotide of at least about 16 nucleotides in length comprising a sequence represented by the following formula:

$$5'\ X_1X_2X_3\ Pu_1\ Py_2\ CpG\ Pu_3\ Py_4\ X_4X_5X_6(W)_M\ (G)_N\text{-}3'$$

wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10

wherein $X_1X_2X_3$ Pu Py and Pu Py $X_4X_5X_6$ are self complementary.

Claims 9-10 (canceled).

Claim 11 (canceled).

Claim 12 (currently amended): The oligodeoxynucleotide of claim [[1]] 8, comprising any one of

GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);

AAGGTCAACG TTGAAAAAAA (SEQ ID NO: 35);

GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1); GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1); GGTGCGTCGACGCAGGGGGG SEQ ID NO: 31);

GGTGCGTCGATGCAGGGGGG (SEQ ID NO: 7); GGTGCACCGGTGCAGGGGGG (SEQ ID NO: 2);

GTCGACGTCGAC (SEQ ID NO: 54);

GGTGCATCGATGCAGGGGG (SEQ ID NO: 73);

GGCGTCGACG GGG (SEQ ID NO: 74);

GGTGCATCGATGCGAGAGA (SEQ ID NO: 87);

TCGGATGTTCTC (SEQ ID NO: 113), or

GGTCCATCGATCCAGGGGGG (SEQ ID NO: 138).

Claim 13 (currently amended): The oligodeoxynucleotide ~~of any of claim 1~~ 8, wherein the oligodeoxynucleotide is modified to prevent degradation.

Claim 14 (currently amended): The oligodeoxynucleotide of claim [[1]] 8, wherein the oligodeoxynucleotide has a phosphate backbone modification.

Claim 15 (original): The oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

Claim 16 (currently amended): The oligodeoxynucleotide of claim [[1]] 8, wherein the oligodeoxynucleotide comprises about 100 nucleotides or less.

Claim 17 (currently amended): The oligodeoxynucleotide of claim 16, wherein the oligodeoxynucleotide comprises about 50 nucleotides or less.

Claim 18 (currently amended): The oligodeoxynucleotide of claim [[9]] 8, wherein the oligodeoxynucleotide comprises about 18 to about 30 nucleotides.

Claim 19 (currently amended): An oligodeoxynucleotide delivery complex comprising the oligodeoxynucleotide of claim [[1]] 8 and a targeting moiety.

Claim 20 (original): The oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

Claim 21 (currently amended): The oligodeoxynucleotide of delivery complex of claim 19, wherein the oligodeoxynucleotide and the targeting moiety are covalently linked.

Claim 22 (currently amended): A pharmacological composition comprising the oligodeoxynucleotide of claim [[1]] $\underline{8}$ and a pharmacologically acceptable carrier.

Claim 23-59 (canceled).

Claim 60 (new): The oligodeoxynucleotide of claim 8, wherein N is about 6.

Claim 61 (new): The oligodeoxynucleotide of claim 8, wherein Pu_1 Py_2 CpG Pu_3 Py_4 comprise phosphodiester bases.

Claim 62 (new): The oligodeoxynucleotide of claim 61, wherein Pu_1 Py_2 CpG Pu_3 Py_4 are phosphodiester bases.

Claim 63 (original): The oligodeoxynucleotide of claim 61, wherein $X_1X_2X_3$ and $X_4X_5X_6(W)_M (G)_N$ comprise phosphodiester bases.

Claim 64 (new): The oligodeoxynucleotide of claim 61, wherein $X_1X_2X_3$ comprises one or more phosphothioate bases.

Claim 65 (new): The oligodeoxynucleotide of claim 61, wherein $X_4X_5X_6(W)_M (G)_N$ comprises one or more phosphothioate bases.

Claim 66 (new): The oligodeoxynucleotide of claim 8, wherein the oligodeoxynucleotide comprises the sequence

5'-X_1X_2TGCATCGATGCAGGGGGG-3' (SEQ ID NO:12);

5'- X_1X_2TGCACCGGTGCAGGGGGG-3' (SEQ ID NO:13);

5'- X_1X_2TGCGTCGACGCAGGGGGG-3'; (SEQ ID NO:)15;

5'- X_1X_2TGCGTCGATGCAGGGGGG -3'; (SEQ ID NO:16);

5'- X_1X_2TGCGCCGGCGCAGGGGGG-3;'(SEQ ID NO:17);

5'- X_1X_2TGCGCCGATGCAGGGGGG-3'(SEQ ID NO:18);

5'- X_1X_2TGCATCGACGCAGGGGGG-3'(SEQ ID NO:19); or.

5'- X_1X_2TGCGTCGGTGCAGGGGGG-3'(SEQ ID NO:20),

wherein X_1 is a G or not base and X_2 is a G or no base.